GO:1901740 negative regulation of myoblast fusion: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901740 (negative regulation of myoblast fusion) describes any process that stops, prevents, or reduces the frequency, rate, or extent of myoblast fusion, a critical step in skeletal muscle development and regeneration.
• Myoblast fusion is a multistep process requiring actin cytoskeleton remodeling, membrane apposition, and fusogenic protein activity; negative regulators act at each of these steps to ensure proper muscle size and function.
• Key negative regulators include Rab44, which controls fusogenic protein transport and mTORC1 signaling, and DA-Raf, a dominant-negative Ras-ERK pathway regulator essential for myocyte differentiation.
• MicroRNAs such as miR-205 can negatively regulate fusion by targeting the myomaker gene, highlighting post-transcriptional control of myoblast fusion.
• Dysregulation of myoblast fusion is linked to fusion-negative rhabdomyosarcoma, where HES1-YAP1-CDKN1C and TWIST2-mediated chromatin remodeling drive tumorigenesis.
• Understanding negative regulation of myoblast fusion informs regenerative medicine and cancer biology, with CRISPR knockout, knock-in, and overexpression models enabling causal gene studies.
Description
Myoblast fusion is the fundamental cellular process by which mononucleated myoblasts merge to form multinucleated myofibers during skeletal muscle development, growth, and regeneration. This process must be tightly controlled: excessive or premature fusion can lead to aberrant muscle architecture, while insufficient fusion contributes to muscle wasting and impaired repair. The Gene Ontology term GO:1901740, negative regulation of myoblast fusion, captures the biological processes that restrain this fusion reaction, ensuring appropriate muscle size and function. Researchers study this term to understand how muscle stem cells (satellite cells) balance activation and quiescence, and how disruptions contribute to neuromuscular disorders and cancers. The regulation of myoblast fusion involves a complex interplay of signaling pathways, cytoskeletal dynamics, and membrane trafficking. Negative regulators such as Rab44 and DA-Raf have been identified as critical brakes on fusion, and their dysfunction is associated with disease states including fusion-negative rhabdomyosarcoma. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:1901740, covering its definition, mechanisms, key genes, disease relevance, and experimental models for study.
negative regulation of myoblast fusion At A Glance
| GO ID | GO:1901740 |
|---|---|
| GO term | negative regulation of myoblast fusion |
| Ontology | biological_process |
| Synonym | down regulation of myoblast fusion, down-regulation of myoblast fusion, downregulation of myoblast fusion, inhibition of myoblast fusion |
| Major function | Restrains the frequency, rate, or extent of myoblast fusion during muscle development and regeneration |
| Related processes | Myoblast differentiation, muscle regeneration, satellite cell activation |
| Key regulators | Rab44, DA-Raf, miR-205, HES1, YAP1, TWIST2 |
| Disease relevance | Fusion-negative rhabdomyosarcoma, neuromuscular disorders |
What Is GO:1901740?
GO:1901740, negative regulation of myoblast fusion, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of myoblast fusion. In other words, it encompasses molecular and cellular events that act as brakes on the merging of myoblasts into multinucleated myotubes. This regulation is essential for proper muscle development and regeneration, preventing excessive or inappropriate fusion that could disrupt tissue architecture.
Why Is negative regulation of myoblast fusion Important in Cell Biology?
Negative regulation of myoblast fusion is crucial for maintaining muscle homeostasis and preventing pathological conditions. Without proper inhibitory control, myoblasts may fuse aberrantly, leading to disrupted muscle architecture and impaired function. This process is also implicated in muscle regeneration after injury, where satellite cells must proliferate and differentiate in a coordinated manner. Moreover, dysregulation of fusion regulators is linked to fusion-negative rhabdomyosarcoma, a pediatric cancer characterized by defective myogenic differentiation. Understanding the negative regulators of myoblast fusion provides insights into muscle biology and potential therapeutic targets for muscle-wasting diseases and cancers.
• Ensures proper muscle size and architecture by preventing excessive myoblast fusion.
• Regulates satellite cell behavior during muscle regeneration after injury.
• Dysregulation contributes to fusion-negative rhabdomyosarcoma, a soft-tissue cancer.
• Involved in neuromuscular disorders where satellite cell dysfunction impairs repair.
• Provides targets for therapeutic intervention in muscle-wasting conditions.
• Key to understanding post-transcriptional control via microRNAs like miR-205.
• Links membrane trafficking and mTORC1 signaling to muscle differentiation.
• Highlights the role of Ras-ERK pathway inhibitors like DA-Raf in myogenesis.
• Informs CRISPR-based models for causal gene studies in muscle biology.
• Relevant to regenerative medicine and tissue engineering applications.
What Happens During negative regulation of myoblast fusion?
Inhibition of Fusogenic Protein Activity
In simple terms: This step blocks the proteins that directly merge cell membranes.
Myoblast fusion requires specific fusogenic proteins, such as myomaker, to mediate membrane merging. Negative regulation can occur through the suppression of these proteins. For example, microRNA miR-205 targets the myomaker gene, reducing its expression and thereby inhibiting fusion in porcine myoblasts. This post-transcriptional control ensures that fusion occurs only when appropriate, preventing premature or excessive myotube formation.
Control of Fusogenic Protein Transport
In simple terms: This step regulates how fusion proteins are moved to the cell surface.
Rab44, a member of the Rab GTPase family, negatively regulates myoblast differentiation by controlling the transport of fusogenic proteins and mTORC1 signaling. Rab44 depletion enhances myoblast fusion, indicating that it acts as a brake on the fusion process by interfering with the trafficking of proteins required for membrane fusion. This highlights the importance of intracellular transport in regulating myoblast fusion.
Suppression of Differentiation Signaling
In simple terms: This step dampens the signals that tell muscle cells to differentiate and fuse.
DA-Raf, a dominant-negative regulator of the Ras-ERK pathway, is essential for skeletal myocyte differentiation, including myoblast fusion and apoptosis. By inhibiting the Ras-ERK pathway, DA-Raf modulates the differentiation program, ensuring that fusion occurs in a controlled manner. This suggests that negative regulation of myoblast fusion can occur through interference with key signaling cascades that promote differentiation.
Transcriptional Repression of Fusion Genes
In simple terms: This step turns off genes that promote fusion at the DNA level.
Transcriptional regulators such as HES1 and TWIST2 can repress the expression of genes required for myoblast fusion. In fusion-negative rhabdomyosarcoma, HES1 interacts with YAP1 and CDKN1C to block differentiation, while TWIST2 mediates chromatin remodeling that promotes a fusion-negative state. These mechanisms illustrate how negative regulation at the transcriptional level can prevent myoblast fusion and contribute to disease.
Key Genes Involved in GO:1901740 negative regulation of myoblast fusion
The following genes and proteins have been experimentally implicated in the negative regulation of myoblast fusion, based on verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Rab44 | Negatively regulates myoblast differentiation by controlling fusogenic protein transport and mTORC1 signaling | Knockout enhances fusion; potential target for muscle regeneration |
| DA-Raf | Dominant-negative regulator of Ras-ERK pathway; essential for myocyte differentiation | Modulates fusion and apoptosis; studied in skeletal muscle development |
| miR-205 | MicroRNA targeting myomaker; inhibits myoblast fusion | Post-transcriptional regulator; relevant to porcine muscle growth |
| Myomaker | Fusogenic protein; target of miR-205 | Essential for fusion; negative regulation via miR-205 |
| HES1 | Transcriptional repressor; interacts with YAP1 and CDKN1C | Involved in fusion-negative rhabdomyosarcoma |
| YAP1 | Transcriptional co-activator; interacts with HES1 | Component of HES1-YAP1-CDKN1C functional interaction |
| CDKN1C | Cyclin-dependent kinase inhibitor; part of HES1-YAP1 axis | Tumor suppressor in fusion-negative rhabdomyosarcoma |
| TWIST2 | Transcription factor; mediates chromatin remodeling | Promotes fusion-negative rhabdomyosarcoma |
| mTORC1 | Signaling complex; regulated by Rab44 | Controls protein synthesis and differentiation |
| Ras | Small GTPase; upstream of ERK pathway | Modulated by DA-Raf; affects myoblast fusion |
| ERK | Kinase; downstream of Ras | Inhibited by DA-Raf; influences differentiation |
| MyoD | Myogenic transcription factor | Master regulator of myogenesis; indirectly affected by negative regulators |
| Myogenin | Myogenic transcription factor | Promotes differentiation; may be repressed in fusion-negative states |
| Pax7 | Satellite cell marker | Maintains quiescence; balance with fusion regulators |
| Myf5 | Myogenic determination factor | Early myogenic commitment; interplay with negative regulators |
| MRF4 | Myogenic regulatory factor | Involved in muscle differentiation |
| Six1 | Homeodomain transcription factor | Regulates myogenesis; potential crosstalk with fusion inhibitors |
| Eya1 | Transcriptional co-activator | Part of myogenic regulatory network |
How Is negative regulation of myoblast fusion Regulated?
Negative regulation of myoblast fusion is controlled by multiple signaling pathways and molecular brakes. The Ras-ERK pathway is modulated by DA-Raf, which acts as a dominant-negative regulator to prevent excessive differentiation signals. Rab44 controls the transport of fusogenic proteins and mTORC1 signaling, thereby gating the availability of fusion machinery. Post-transcriptional regulation by microRNAs such as miR-205 fine-tunes the expression of fusogenic proteins like myomaker. Additionally, transcriptional repressors like HES1 and TWIST2 can block the expression of myogenic genes, contributing to a fusion-negative state in pathological conditions. These layers of regulation ensure that myoblast fusion occurs only under appropriate conditions.
negative regulation of myoblast fusion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HES1 | Fusion-negative rhabdomyosarcoma | Knockout in rhabdomyosarcoma cell lines to assess differentiation |
| TWIST2 | Fusion-negative rhabdomyosarcoma | Overexpression and knockout in myoblast lines to study chromatin remodeling |
| Rab44 | Muscle regeneration and atrophy | Knockout mice or C2C12 cells to evaluate fusion efficiency |
| DA-Raf | Skeletal muscle differentiation | Knockout and rescue in myoblast cultures |
| miR-205 | Porcine muscle growth | Overexpression and inhibition in porcine myoblasts |
Fusion-Negative Rhabdomyosarcoma
Fusion-negative rhabdomyosarcoma is a pediatric soft-tissue cancer characterized by defective myogenic differentiation and absence of PAX3-FOXO1 fusion genes. HES1, YAP1, and CDKN1C form a functional interaction that promotes tumorigenesis by blocking differentiation. TWIST2-mediated chromatin remodeling also drives a fusion-negative state, contributing to tumor progression. Targeting these negative regulators of myoblast fusion may offer therapeutic strategies for this aggressive cancer.
Neuromuscular Disorders and Satellite Cell Dysfunction
Muscle satellite cell dysfunction underlies several neuromuscular disorders, where impaired activation or differentiation leads to failed regeneration. Negative regulators of myoblast fusion, such as Rab44, may contribute to satellite cell-opathies by restraining fusion when it is needed for repair. Understanding these mechanisms could inform therapies for muscular dystrophies and age-related muscle wasting.
Muscle Regeneration and Atrophy
Proper regulation of myoblast fusion is essential for muscle regeneration after injury. Excessive negative regulation can impair regeneration, leading to muscle atrophy and weakness. Conversely, loss of negative regulators may cause aberrant fusion and disrupted muscle architecture. DA-Raf and Rab44 are key players in balancing fusion and differentiation, and their dysregulation is linked to impaired muscle repair.
From negative regulation of myoblast fusion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does Rab44 negatively regulate myoblast fusion? | Rab44 knockout C2C12 myoblasts via CRISPR |
| What is the role of DA-Raf in Ras-ERK signaling during fusion? | DA-Raf knockout and point-mutation knock-in in mouse myoblasts |
| How does miR-205 target myomaker? | miR-205 overexpression and 3'UTR reporter assays in porcine myoblasts |
| Can HES1-YAP1 interaction be disrupted to promote differentiation? | HES1 knockout or point mutations in rhabdomyosarcoma cells |
| Does TWIST2 chromatin remodeling block fusion? | TWIST2 knockout and tagged knock-in in myoblast lines |
| What is the role of mTORC1 in Rab44-mediated fusion inhibition? | mTORC1 knockout or overexpression in Rab44-deficient myoblasts |
How to Study the negative regulation of myoblast fusion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effects on myoblast fusion | Identify negative regulators like Rab44 |
| RNA-seq | Transcriptional changes | Profile fusion-negative rhabdomyosarcoma |
| Immunofluorescence | Fusion index and myotube morphology | Assess fusion efficiency in vitro |
| Co-immunoprecipitation | Protein-protein interactions | Map Rab44 effectors |
| Western blot | Protein expression levels | Validate knockdown or overexpression |
| Luciferase reporter assay | 3'UTR targeting by miRNAs | Confirm miR-205 regulation of myomaker |
| Chromatin immunoprecipitation | Transcription factor binding | Study TWIST2-mediated remodeling |
| Live-cell imaging | Dynamics of fusion events | Real-time monitoring of myoblast fusion |
CRISPR Knockout Screens
CRISPR knockout screens can identify negative regulators of myoblast fusion by disrupting candidate genes and measuring fusion efficiency. For example, knocking out Rab44 in C2C12 myoblasts enhances fusion, confirming its inhibitory role. High-throughput screens targeting all kinases or GTPases could uncover novel fusion brakes.
RNA Sequencing and Transcriptomics
RNA-seq can reveal changes in gene expression upon manipulation of negative regulators. For instance, Rab44 knockout alters the expression of fusogenic proteins and mTORC1 targets. Transcriptomic profiling of fusion-negative rhabdomyosarcoma cells has identified HES1 and TWIST2 as key drivers.
Imaging and Fusion Assays
Live-cell imaging and immunofluorescence can directly visualize myoblast fusion events. Myosin heavy chain staining and nuclei counting are standard readouts. Fusion index quantification in C2C12 cells is widely used to assess the impact of negative regulators.
Proteomics and Interactomics
Proteomic approaches can identify proteins interacting with negative regulators. For example, immunoprecipitation of Rab44 followed by mass spectrometry can reveal its effectors in membrane trafficking. Similarly, DA-Raf interactors in the Ras-ERK pathway can be mapped.
How CRISPR Can Be Used to Study GO:1901740 negative regulation of myoblast fusion
Knockout
CRISPR knockout is used to ablate negative regulators of myoblast fusion, such as Rab44 or DA-Raf, to assess whether their loss enhances fusion. This approach provides causal evidence for their inhibitory roles and can be performed in C2C12 myoblasts or primary satellite cells.
Point Mutation
Point mutations can be introduced to dissect specific domains or phosphorylation sites in negative regulators. For example, mutating the GTPase domain of Rab44 can reveal its role in membrane trafficking independent of mTORC1 signaling. Similarly, point mutations in DA-Raf can separate its Ras-binding from ERK-inhibitory functions.
Knock-in
Knock-in of tagged versions of negative regulators, such as GFP-Rab44 or HA-DA-Raf, allows for live-cell imaging and proteomic analysis. This approach enables tracking of protein localization and interactions during myoblast fusion without altering endogenous expression levels.
Overexpression
Overexpression of negative regulators like miR-205 or TWIST2 can suppress myoblast fusion, providing gain-of-function evidence. This is particularly useful for studying microRNAs, where overexpression mimics their inhibitory effects on target genes like myomaker.
How EDITGENE Supports negative regulation of myoblast fusion Research
Researchers studying negative regulation of myoblast fusion-related genes often need to determine whether a candidate gene is causally involved in restraining fusion or is merely correlated with the process. CRISPR-based models provide the gold standard for establishing causality, enabling precise genetic perturbations in relevant cell types such as myoblasts and satellite cells.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of myoblast fusion research.
Frequently Asked Questions About negative regulation of myoblast fusion
What is GO:1901740?
GO:1901740 is the Gene Ontology term for negative regulation of myoblast fusion, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of myoblast fusion.
What genes are involved in negative regulation of myoblast fusion?
Key genes include Rab44, DA-Raf, miR-205, HES1, YAP1, CDKN1C, and TWIST2, as identified in published studies.
How does Rab44 inhibit myoblast fusion?
Rab44 negatively regulates myoblast differentiation by controlling fusogenic protein transport and mTORC1 signaling.
What is the role of miR-205 in myoblast fusion?
miR-205 targets the myomaker gene to inhibit myoblast fusion in porcine myoblasts.
How is negative regulation of myoblast fusion linked to cancer?
Dysregulation of fusion regulators like HES1 and TWIST2 contributes to fusion-negative rhabdomyosarcoma, a pediatric cancer.
What experimental models are used to study negative regulation of myoblast fusion?
Common models include C2C12 myoblasts, primary satellite cells, and rhabdomyosarcoma cell lines, with CRISPR knockout, overexpression, and imaging assays.
What is the function of DA-Raf in myoblast fusion?
DA-Raf is a dominant-negative regulator of the Ras-ERK pathway that is essential for skeletal myocyte differentiation, including myoblast fusion.
How can CRISPR be used to study negative regulation of myoblast fusion?
CRISPR knockout, point mutation, knock-in, and overexpression can establish causal roles of candidate genes in restraining fusion.
What diseases are associated with defective negative regulation of myoblast fusion?
Fusion-negative rhabdomyosarcoma and neuromuscular disorders with satellite cell dysfunction are associated with dysregulated fusion.
What methods measure myoblast fusion efficiency?
Fusion index quantification by immunofluorescence, live-cell imaging, and myosin heavy chain staining are standard methods.
Conclusion
Negative regulation of myoblast fusion (GO:1901740) is a critical biological process that ensures proper muscle development and regeneration by restraining the fusion of myoblasts into myotubes. Key regulators such as Rab44, DA-Raf, miR-205, HES1, and TWIST2 act at multiple levels to control this process, and their dysregulation is linked to diseases including fusion-negative rhabdomyosarcoma and neuromuscular disorders. Understanding these mechanisms offers opportunities for therapeutic intervention and regenerative medicine. CRISPR-based models provide powerful tools to dissect the causal roles of these genes, and EDITGENE offers comprehensive services to support such research.
References
- 1. Millay DP. 2022. Regulation of the myoblast fusion reaction for muscle development, regeneration, and adaptations.. Exp Cell Res 415(2):113134 PMID: 35367215
- 2. Ganassi M et al.. 2022. Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.. Eur J Transl Myol 32(1) PMID: 35302338
- 3. Ma J et al.. 2023. miR-205 Regulates the Fusion of Porcine Myoblast by Targeting the Myomaker Gene.. Cells 12(8) PMID: 37190016
- 4. Takahashi K et al.. 2019. DA-Raf, a dominant-negative regulator of the Ras-ERK pathway, is essential for skeletal myocyte differentiation including myoblast fusion and apoptosis.. Exp Cell Res 376(2):168-180 PMID: 30742807
- 6. Kovach AR et al.. 2022. Identification and targeting of a HES1-YAP1-CDKN1C functional interaction in fusion-negative rhabdomyosarcoma.. Mol Oncol 16(20):3587-3605 PMID: 36037042
- 7. Shah AM et al.. 2023. TWIST2-mediated chromatin remodeling promotes fusion-negative rhabdomyosarcoma.. Sci Adv 9(17):eade8184 PMID: 37115930
- 8. Tanimoto A et al.. 2023. Rab44 negatively regulates myoblast differentiation by controlling fusogenic protein transport and mTORC1 signaling.. J Cell Biochem 124(10):1486-1502 PMID: 37566644
